Immunosuppression modifications based on an immune response assay: Results of a randomized, controlled trial

Transplantation

Volumn 99, Issue 8, 2015, Pages 1625-1632

  Ravaioli, Matteo ^a   Neri, Flavia ^a   Lazzarotto, Tiziana ^b   Bertuzzo, Valentina Rosa ^a   Gioia, Paolo Di ^a   Stacchini, Giacomo ^a   Morelli, Maria Cristina ^a   Ercolani, Giorgio ^a   Cescon, Matteo ^a   Chiereghin, Angela ^b   Gaudio, Massimo Del ^a   Cucchetti, Alessandro ^a   Pinna, Antonio D ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; COTRIMOXAZOLE; GANCICLOVIR; NYSTATIN; STEROID; TACROLIMUS; VALGANCICLOVIR; BIOLOGICAL MARKER; DIAGNOSTIC KIT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; ASPERGILLOSIS; BACTEREMIA; BACTERIAL INFECTION; BILIARY TRACT INFECTION; CANDIDEMIA; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; EVENING DOSAGE; FEMALE; GRAFT RECIPIENT; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 8; IMMUNE CELL FUNCTION ASSAY; IMMUNE FUNCTION TEST; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MYCOSIS; PARALLEL DESIGN; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; URINARY TRACT INFECTION; VIRUS INFECTION; WEST NILE VIRUS; ADVERSE EFFECTS; AGED; BLOOD; CASE REPORT; DEVICES; DIAGNOSTIC KIT; DOSE CALCULATION; DRUG COMBINATION; DRUG EFFECTS; DRUG MONITORING; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; ITALY; MIDDLE AGED; MORTALITY; OPPORTUNISTIC INFECTIONS; PREDICTIVE VALUE; PROCEDURES; TREATMENT OUTCOME;

ADENOSINE TRIPHOSPHATE; ADULT; AGED; BIOLOGICAL MARKERS; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; ITALY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MONITORING, IMMUNOLOGIC; OPPORTUNISTIC INFECTIONS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REAGENT KITS, DIAGNOSTIC; STEROIDS; TACROLIMUS; TREATMENT OUTCOME;

EID: 84942435776     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000650     Document Type: Article

References (42)

1. Mells G Neuberger J. Long-term care of the liver allograft recipient. Semin Liver Dis. 2009;29:102-120.
2. ImmuKnow® Immune Cell Function Assay. Product Insert 2007. Cylex™ Inc., Columbia, MD.
3. He J, Li Y, Zhang H, et al. Immune function assay (ImmuKnow) as a predictor of allograft rejection and infection in kidney transplantation. Clin Transplant. 2013;27:E351-E358.
4. Heikal NM, Bader FM, Martins TB, et al. Immune function surveillance: association with rejection, infection and cardiac allograft vasculopathy. Transplant Proc. 2013;45:376-382.
5. Zhou H, Wu Z, Ma L, et al. Assessing immunologic function through CD4 T-lymphocyte adenosine triphosphate levels by ImmuKnow assay in Chinese patients following renal transplantation. Transplant Proc. 2011;43:2574-2578.
6. Dong JY, Yin H, Li RD, et al. The relationship between adenosine triphosphate within CD4(+) T lymphocytes and acute rejection after liver transplantation. Clin Transplant. 2011;25:E292-E296.
7. Hashimoto K, Miller C, Hirose K, et al. Measurement of CD4+ T-cell function in predicting allograft rejection and recurrent hepatitis C after liver transplantation. Clin Transplant. 2010;24:701-708.
8. Rodrigo E, Lopez-Hoyos M, Corral M, et al. ImmuKnow as a diagnostic tool for predicting infection and acute rejection in adult liver transplant recipients: a systematic review and meta-analysis. Liver Transplant. 2012;18:1245-1253.
9. Xue F, Zhang J, Han L, et al. Immune cell functional assay in monitoring of adult liver transplantation recipients with infection. Transplantation. 2010;89:620-626.
10. Hashimoto K, Miller CM, Quintini C, et al. Impact of Cylex (R) immune cell function assay in predicting acute cellular rejection and recurrence of HCV in liver transplantation. Am J Transplant. 2008;8:612-613.
11. López-Hoyos M, Rodrigo E, Arias M. The usefulness of intracellular adenosine-5'-triphosphate measurement in CD4+ cells in renal transplant. Nefrologia. 2013;33:381-388.
12. Kobashigawa JA, Kiyosaki KK, Patel JK, et al. Benefit of immune monitoring in heart transplant patients using ATP production in activated lymphocytes. J Heart Lung Transplant. 2010;29:504-508.
13. Serban G, Whittaker V, Fan J, et al. Significance of immune cell function monitoring in renal transplantation after thymoglobulin induction therapy. Hum Immunol. 2009;70:882-890.
14. Thai NL, Blisard D, Tom K, et al. Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: Correlation between low T-cell responses and infection. Transplantation. 2006;82:1649-1652.
15. Gautam A, Fischer SA, Yango AF, Gohh RY, Morrissey PE, Monaco AP. Cell mediated immunity (CMI) and post-transplant viral infections-role of a functional immune assay to titrate immunosuppression. Int Immunopharmacol. 2006;6:2023-2026.
16. Cabrera R, Ararat M, Soldevila-Pico C, et al. Using an mmune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients. Liver Transpl. 2009;15:216-222.
17. Tanaka T, Takatsuki M, Soyama A, et al. Evaluation of immune function under conversion from Prograf to Advagraf in living donor liver transplantation. Ann Transplant. 2013;18:293-298.
18. San Segundo D, Fernández-Fresnedo G, Gago M, et al. Number of peripheral blood regulatory T cells and lymphocyte activation at 3 months after conversion to mTOR inhibitor therapy. Transplant Proc. 2010;42:2871-2873.
19. Berglund D, Bengtsson M, Biglarnia A, et al. Screening of mortality in transplant patients using an assay for immune function. Transpl Immunol. 2011;24:246-250.
20. Uemura T, Riley TR, Khan A, et al. Immune functional assay for immunosuppressive management in post-transplant malignancy. Clin Transplant. 2011;25:E32-E37.
21. Te HS, Dasgupta KA, Cao D, et al. Use of immune function test in monitoring immunosuppression in liver transplant recipients. Clin Transplant. 2012;26:826-832.
22. Kowalski R, Post D, Schneider MC, et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant. 2003;17:77-88.
23. de Simone P, Beckebaum S, Koneru B, Fung J, Saliba F. Everolimus with reduced tacrolimus in liver transplantation. Am J Transplant. 2013;13:1373-1374.
24. Lee RG, Tsamandas AC, Demetris AJ. Large cell change (liver cell dysplasia) and hepatocellular carcinoma in cirrhosis: matched casecontrol study, pathological analysis, and pathogenetic hypothesis. Hepatology. 1997;26:1415-1422.
25. Signore A. About inflammation and infection. EJNMMI Research. 2013;3:8.
26. Humar A, Michaels M, ASTID. Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006;6:262-274.
27. Bone RC. Sepsis and coagulation. An important link. Chest. 1992; 101:594-596.
28. Razonable RR. Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J Gastroenterol. 2008;14: 4849-4860.
29. Mendler M, Kwok H, Franco E, Baron P, Weissman J, Ojogho O. Monitoring peripheral blood CD4+ adenosine triphosphate activity in a liver transplant cohort: insight into the interplay between hepatitis C virus infection and cellular immunity. Liver Transpl. 2008;14:1313-1322.
30. Natsuda K, Soyama A, Takatsuki M, et al. The efficacy of the ImmuKnow assay for evaluating the immune status in human immunodeficiency virus and hepatitisC virus-coinfected patients. Transplant Proc. 2014;46:733-735.
31. Mizuno S, Muraki Y, Nakatani K, et al. Immunological aspects in late phase of living donor liver transplant patients: usefulness ofmonitoring peripheral blood CD4+ adenosine triphosphate activity. Clin Dev Immunol. 2013; 2013:982163.
32. Zhou T, Xue F, Han LZ, et al. Invasive fungal infection after liver transplantation: risk factors and significance of immune cell function monitoring. J Dig Dis. 2011;12:467-475.
33. Ikegami T, Imai D, Wang H, et al. D-MELD as a predictor of early graft mortality in adult-to-adult living-donor liver transplantation. Transplantation. 2014;97:457-462.
34. Hwang S, Kim KH, Song GW, et al. Peritransplant monitoring of immune cell function in adult living donor liver transplantation. Transplant Proc. 2010;42:2567-2571.
35. Li RD, Sun Z, Dong JY, et al. A quantitative assessment model of T-cell immune function for predicting risks of infection and rejection during the early stage after liver transplantation. Clin Transplant. 2013;27:666-672.
36. Ravaioli M, Grazi GL, Ballardini G, et al. Liver transplantation with the Meld system: a prospective study from a single European center. Am J Transplant. 2006;6:1572-1577.
37. Roayaie K, Feng S. Allocation policy for hepatocellular carcinoma in the MELD era: room for improvement? Liver Transpl. 2007;13(11 Suppl 2):S36-S43.
38. Agopian VG, Petrowsky H, Kaldas FM, et al. The evolution of liver transplantation during 3 decades: analysis of 5347 consecutive liver transplants at a single center. Ann Surg. 2013;258:409-421.
39. Silberhumer GR, Hetz H, Rasoul-Rockenschaub S, et al. Is MELD score sufficient to predict not only death on waiting list, but also posttransplant survival? Transpl Int. 2006;19:275-281.
40. Fishman JA. Infection in solid-organ transplant recipients. N Engl JMed. 2007;357:2601-2614.
41. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guidelines for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1-S155.
42. Lerut JMJ, Verbaandert C, Talpe S, et al. Tacrolimus monotherapy in liver transplantation: one-year results of a prospective, randomized, doubleblind, placebo-controlled study. Ann Surg. 2008;248:956-967.